Recent News

• 02.27.2025 - Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
• 02.12.2025 - Royalty Pharma Announces R&D Funding Collaboration with Biogen
• 02.11.2025 - Royalty Pharma Reports Q4 and Full Year 2024 Results
• 02.11.2025 - Royalty Pharma Reports Q4 and Full Year 2024 Results
• 01.29.2025 - Royalty Pharma Announces Sale of Morphosys Development Funding Bonds
• 01.28.2025 - Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
• 01.28.2025 - Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Recent Filings

• 02.21.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.13.2025 - PREM14A Preliminary proxy statements relating to merger or acquisition
• 02.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.11.2025 - 8-K Current report
• 02.11.2025 - EX-99.1 EX-99.1
• 02.04.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.17.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 01.16.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material